Given the pivotal role of CD8+ T cells in cytotoxic immune responses, where they kill tumor cells directly (18), it is also notable that the combination therapy resulted in a higher percentage of circulating and tumor-infiltrating CD8+ T cells (gated as CD45+CD3+B220-CD4-CD8+) (Figures 2B, E). The gene discussed is CD8A; the disease is neoplasm.